30 September 2025 - 01 October 2025
30 September – 01 October
Join Labcorp at Biomarkers and Precision Medicine 2025
Advancing precision medicine for greater patient access to your breakthrough therapy
Labcorp provides integrated solutions across the entire precision medicine pathway—from biomarker identification and clinical trial assay development to CDx validation and commercialization.
Discover our expertise across testing modalities and therapeutic areas
- Strategic guidance from our Biomarker Solution Center to inform development
- Collaborative CDx programmes with regulatory and diagnostic specialists
- Sample-to-report precision oncology services across our international laboratory network
Join us at Biomarkers 2025, 30 September – 01 October, to discover how Labcorp supports the delivery of innovative therapies to patients across Europe and beyond.
Join us for a pre-event half-day workshop
29 September | 1 - 5:30 p.m.
Empowering Precision Medicine with Comprehensive Insights and Global Scalability
This workshop offers a deep dive into accelerating precision medicine programs, reducing development risks and enhancing successful outcomes using insights across various therapeutic areas.
Attendees will gain valuable insights into maximizing ROI in biomarker-driven development and learn from industry experts sharing real-world success focused on:
- Balancing scientific innovation with operational efficiency to enhance global reach and adoption
- Optimizing study design for enhanced outcomes in critical therapeutic areas including oncology, neurology, cardiometabolic and rare diseases using novel biomarkers
- Leveraging the right technology platform in key areas such as flow cytometry, digital pathology, and next-generation sequencing to advance immune profiling, enable AI-generated insights and unlock new genomic targets
Join us for our speaking engagements
30 September | 9:40 a.m.
Liquid biopsy-based opportunities to accelerate solid tumor drug development strategies
Speaker: Mark Sausen, PhD, Executive Director, Head of Technology Innovation
Location: Biomarkers & Precision Medicine – Track 1: Biomarker Identification, Validation, In Oncology, IO, Immunology
Abstract:
- Overview of circulating tumor DNA approaches to address the solid tumor cancer care continuum
- Circulating tumor DNA strategies to complement radiographic and survival-based endpoints in patients with advanced and metastatic cancer
- Molecular residual disease analyses
30 September | 11:25 a.m.
Pixels with Purpose: Advancing Precision Medicine with Digital Pathology
Speaker: Paul Mesange, PhD, Global Director of Operations
Location: Digital Pathology & AI – Track 7: Image Analysis & AI
Abstract:
Precision medicine demands more than just targeted therapies—it requires targeted tools. Digital pathology is emerging as a critical enabler in identifying, validating, and operationalizing biomarkers that drive patient stratification and therapeutic success. In this session, we’ll share how AI-powered image analysis, multiplex imaging, and robust data platforms help to deepen biological understanding and accelerate drug development. Through concrete examples, we’ll demonstrate how digital pathology workflows can integrate seamlessly into biomarker discovery and companion diagnostic programs.
- Maximize Biomarker Insights: Harness AI and multiplex data to explore tumor heterogeneity and immune landscapes
- Build Regulatory-Ready Data: Future-proof your pathology data for diagnostics, submission, and reuse
- Scale with Confidence: Align digital pathology with biomarker-driven study designs and evolving global standards